The effect of the fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation

Blood

Volumn 88, Issue 3, 1996, Pages 1019-1025

  Kupfer, Gary M ^a   D'Andrea, Alan D ^b  

^a Div of Cellular Molecular Biology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CAFFEINE; CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; HYDROGEN PEROXIDE; MITOMYCIN C; PROTEIN P53; VINBLASTINE;

APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CELL CYCLE G2 PHASE; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FANCONI ANEMIA; GAMMA IRRADIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0029744915     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.1019.bloodjournal8831019     Document Type: Article

References (68)

1. Fanconi G: Familial constitutional panmyelocytopathy. Fanconi's anemia (FA). I. Clinical aspects. Semin Hematol 4:233, 1967
2. Strathdee CA, Buchwald M: Molecular and Cellular Biology of Fanconi Anemia. Am J Pedi Hemat/Oncol 14:177, 1992
3. Liu J, Buchwald M, Walsh C, Young N: Fanconi anemia and novel strategies for therapy. Blood 84:3995, 1994
4. Auerbach AD: Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 21:731, 1993
5. Auerbach A, Adler B, O'Reilly R, Kirkpatrick D, Chaganit R: Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: Relevance to bone marrow transplantation. Cancer Genet Cytogenet 9:25, 1983
6. Kwee M, Poll E, Kamp JVD: Unusual response to bifunctional alkylating agents in a case of Fanconi anemia. Hum Genet 64:384, 1983
7. Strathdee CA, Duncan AMV, Buchwald M: Evidence for at least four Fanconi Anemia genes including FACC on chromosome 9. Nat Genet 1:196, 1992
8. Moustacchi E, Papadopoulo D, Diatloff-Zito C, Buchwald M: Two complementation groups of Fanconi's anemia differ in their phenotypic response to a DNA cross-linking treatment. Hum Genet 75:45, 1987
9. Duckworth-Rysiecki G, Cornish K, Clarke CA, Buchwald M: Identification of two complementation groups in Fanconi Anemia. Somat Cell Mol Genet 11:35, 1985
10. Joenje H, LoTen F, Oostra A, Berkel CV, Rooimans M, Schroeder S, Kurth T, Wegner R, Gille J, Buchwald M, Arwert F: Classification of Fanconi Anemia patients by complementation analysis: Evidence for a fifth genetic subtype. Blood 86:2156, 1995
11. Strathdee CA, Gavish H, Shannon WR, Buchwald M: Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 356:763, 1992
12. Strathdee CA, Gavish H, Shannon W, Buchwald M: Cloning of cDNAs for Fanconi's Anemia by functional complementation (Correction). Nature 358:434, 1992
13. Verlander PC, Lin JD, Udono MU, Zhang Q, Gibson RA, Mathew CG, Auerbach AD: Mutation analysis of the Fanconi anemia gene FACC. Am J Hum Genet 54:595, 1994
14. Whitney MA, Saito H, Jakobs PM, Gibson RA, Moses RE, Grompe M: A common mutation in the FACC gene causes Fanconi anemia in Ashkenazi Jews. Nat Genet 4:202, 1993
15. Sasaki MS, Tonomura A: A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross linking agents. Cancer Res 33:1829, 1973
16. Fujiwara Y: Defective repair of mitomycin C cross-links in Fanconi's anemia and loss in confluent normal human and Xeroderma pigmentosum cells. Biochim Biophys Acta 699:217, 1982
17. Yamashita T, Barber DL, Zhu Y, Wu N, D'Andrea AD: The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc Natl Acad Sci USA 91:6712, 1994
18. Youssoufian H: Localization of Fanconi anemia C protein to the cytoplasm of mammalian cells. Proc Natl Acad Sci USA 91:7975, 1994
19. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB: Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 290:142, 1981
20. Gille JJP, Wortelboer HM, Joenje H: Antioxidant status of Fanconi anemia fibroblasts. Hum Genet 77:28, 1987
21. Joenje H, Eriksson AW, Frants RR, Arwert F, Houween B: Erythrocyte superoxide dismutase deficiency in Fanconi's anaemia. Lancet 1:204, 1978
22. Saito H, Hammond AT, Moses RE: Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. Mutat Res 294:255, 1993
23. Dutrillaux B, Aurias A, Dutrillaux AM, Buriot D, Prieur M: The cell cycle of lymphocytes in Fanconi anemia. Hum Genet 62:327, 1982
24. Kaiser TN, Lojewski A, Dougherty C, Juergens L, Sahar E, Latt SA: Flow cytometric characterization of the response of Fanconi's Anemia cells to mitomycin C treatment. Cytometry 2:291, 1982
25. Sabatier L, Dutrillaux B: Effect of caffeine in Fanconi anemia: I. Restoration of a normal duration of G2 phase. Hum Genet 79:242, 1988
26. Seyschab H, Bretzel G, Friedl R, Schinlder D, Sun Y, Hoehn H: Modulation of the spontaneous G2 phase blockage in Fanconi anemia cells by caffeine: Differences from cells arrested by X-irradiation. Mutat Res 308:149, 1994
27. Selby C, Sancar A: Molecular mechanisms of DNA repair by caffeine. Proc Natl Acad Sci USA 87:3522, 1990
28. Lau CC, Pardee AB: Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79:2942, 1982
29. Alter BP: Fanconi's anaemia and its variability. Br J Haematol 85:9, 1993
30. Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W, Plunkett B, Vogelstein B, AJ Fornace J: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587, 1992
31. Scherr C: G1 phase progression: Cycling on cue. Cell 79:551, 1994
32. Heichman K, Roberts J: Rules to replicate by. Cell 79:557, 1994
33. Laskey R, Fairman M, Blow J: S phase of the cell cycle. Science 246:609, 1989
34. Lu X, Lane D: Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell 75:765, 1993
35. Rosselli F, Ridet A, Soussi R, Duchaud E, Alapetite C, Moustacchi E: p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. Oncogene 10:9, 1995
36. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo J-W, Lodish HF: The cytoplasmic region of the erythropoietin receptor contains non-overlapping positive and negative growth regulatory domains. Mol Cell Biol 11:1980, 1991
37. Stonesifer K, Xiang J, Wilkinson E, Benson N, Braylan R: Flow cytometric analysis and cytopathology of body cavity fluids. Acta Cytolo 31:125, 1987
38. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248, 1976
39. Walsh C, Neinhuis A, Samulski R, Brown M, Miller J, Young N, Liu J: Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 94:1440, 1994
40. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307, 1993
41. Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304, 1991
42. Ishida R, Buchwald M: Susceptibility of Fanconi's anemia lymphoblasts to DNA cross-linking and alkylating agents. Cancer Res 42:4000, 1982
43. Weksberg R, Buchwald M, Sargent P, Thompson M, Siminovitch L: Specific cellular defects in patients with Fanconi anemia. J Cell Physiol 101:311, 1979
44. Rosselli F, Duchaud E, Averbeck D, Moustacchi E: Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors. Mutat Res 325:137, 1994
45. Akman S, Doroshow J, Burke T, Dizdaroglu M: DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin. Biochemistry 31:3500, 1992
46. Mans D, Lafleur M, Westmijze E, Maanen JV, Schaik MV, Lankelma J, Retel J: Formation of different reaction products with single- and double-stranded DNA by the ortho-quinone and the semiquinone free radical of etoposide (VP-16-213). Biochem Pharmacol 42:2131, 1991
47. Wozniak A, Glisson B, Hande K, Ross W: Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 44:626, 1984
48. Macleod K, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 cell growth, differentiation, and DNA damage. Genes Dev 9:935, 1995
49. Nelson W, Kastan M: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815, 1994
50. Cross S, Sanchez C, Morgan C, Schimke M, Ramel S, Iderda R, Raskind W, Reid B: A p53-dependent mouse spindle checkpoint. Science 267:1353, 1995
51. Zhang Q, Gutsch D, Kenney S: Functional and physical interaction between p53 and BZLFI: implications for EBV latency. MCB 14:1929, 1994
52. Allday M, Sinclair A, Parker G, Crawford D, Farrell P: EBV efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J 14:1382, 1995
53. Nagasawa H, Li C, Maki C, Imrich A, Little J: Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res 55:1842, 1995
54. Lowe S, Schmitt E, Smith S, Osborne B, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362:847, 1993
55. Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M, Wylie A: Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 362:849, 1993
56. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
57. Strasser A, Harris A, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53 independent mechanisms inhibitable by bcl-2. Cell 79:329, 1994
58. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A: Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. MCB 8:531, 1988
59. Michalovitz D, Eliyahu D, Oren M: Overproduction of p53 contributes to SV40 mediated transformation. MCB 6:3531, 1986
60. Oren M, Maltzman W, Levine A: Post-translational regulation of the 54kd cellular tumor antigen in normal and transformed cells. MCB 1:101, 1981
61. Rowley R: Reduction of radiation-induced arrest by caffeine. Radiat Res 129:224, 1992
62. cdc2 activation. Cancer Res 53:1507, 1993
63. Russell K, Wiens L, Demers G, Galloway D, Plon S, Groudine M: Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res 55:1639, 1995
64. +) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55:1643, 1995
65. Pincheira J, Bravo M, Lopez-Saez JF: Fanconi's anemia lymphocytes: Effect of caffeine, adenosine, and niacinamide during G2 prophase. Mutat Res 199:159, 1988
66. Walters R, Gurley L, Tobey R: Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. Biophys J 14:99, 1974
67. Tolmach L, Jones R, Busse P: The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiat Res 71:653, 1977
68. Frazelle J, Harris J, Swift M: Response of Fanconi anemia fibroblasts to adenine and purine analogues. Mutat Res 80:373, 1981